Annual report pursuant to Section 13 and 15(d)

Non-Controlling Interests (Schedule of Non-Controlling Interests in Consolidated Entities) (Details)

v3.22.1
Non-Controlling Interests (Schedule of Non-Controlling Interests in Consolidated Entities) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Noncontrolling Interest [Line Items]    
NCI equity share $ 217,326 $ 153,120
Net loss attributable to non-controlling interests (100,123) (56,459)
Non-controlling interests in consolidated entities 117,203 96,661
UR-1 Therapeutics, Inc [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share (442) (7)
Net loss attributable to non-controlling interests (1,353) (27)
Non-controlling interests in consolidated entities $ (1,795) $ (34)
Non-controlling ownership 34.50% 10.00%
Aevitas [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (4,159) $ (2,370)
Net loss attributable to non-controlling interests (901) (823)
Non-controlling interests in consolidated entities $ (5,060) $ (3,193)
Non-controlling ownership 45.90% 39.00%
Avenue [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ 5,739 $ 5,800
Net loss attributable to non-controlling interests (2,909) (3,974)
Non-controlling interests in consolidated entities $ 2,830 $ 1,826
Non-controlling ownership 82.00% 77.40%
Baergic [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (2,047) $ (1,662)
Net loss attributable to non-controlling interests (39) (97)
Non-controlling interests in consolidated entities $ (2,086) $ (1,759)
Non-controlling ownership 39.00% 39.50%
Cellvation [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (1,413) $ (1,089)
Net loss attributable to non-controlling interests (131) (182)
Non-controlling interests in consolidated entities $ (1,544) $ (1,271)
Non-controlling ownership 21.70% 22.10%
Checkpoint [Member].    
Noncontrolling Interest [Line Items]    
NCI equity share $ 63,464 $ 41,704
Net loss attributable to non-controlling interests (39,226) (13,265)
Non-controlling interests in consolidated entities $ 24,238 $ 28,439
Non-controlling ownership 81.50% 80.40%
Coronado SO [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (290) $ (290)
Net loss attributable to non-controlling interests 0 0
Non-controlling interests in consolidated entities $ (290) $ (290)
Non-controlling ownership 13.00% 13.00%
Cyprium [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (1,397) $ 567
Net loss attributable to non-controlling interests (807) (1,478)
Non-controlling interests in consolidated entities $ (2,204) $ (911)
Non-controlling ownership 29.80% 30.50%
Helocyte [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (5,440) $ (4,986)
Net loss attributable to non-controlling interests (89) (259)
Non-controlling interests in consolidated entities $ (5,529) $ (5,245)
Non-controlling ownership 18.30% 18.80%
JMC [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ 23,150 $ 138
Net loss attributable to non-controlling interests (5,652) 491
Non-controlling interests in consolidated entities $ 17,498 $ 629
Non-controlling ownership 41.60% 7.10%
Mustang [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ 141,527 $ 116,060
Net loss attributable to non-controlling interests (48,518) (36,429)
Non-controlling interests in consolidated entities $ 93,009 $ 79,631
Non-controlling ownership 82.70% 80.90%
Oncogenuity [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (627) $ (82)
Net loss attributable to non-controlling interests (497) (376)
Non-controlling interests in consolidated entities $ (1,124) $ (458)
Non-controlling ownership 24.90% 25.30%
Tamid [Member]    
Noncontrolling Interest [Line Items]    
NCI equity share $ (739) $ (663)
Net loss attributable to non-controlling interests (1) (40)
Non-controlling interests in consolidated entities $ (740) $ (703)
Non-controlling ownership 22.80% 22.80%